Hepatocellular carcinoma: current management.

[1]  T. de Baère,et al.  Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC) , 2007, Cancer.

[2]  S. Fan,et al.  Changing Paradigm in the Management of Hepatocellular Carcinoma Improves the Survival Benefit of Early Detection by Screening , 2008, Annals of surgery.

[3]  W. Scheithauer,et al.  A phase I/II trial of epirubicin and high dose tamoxifen as a potential modulator of multidrug resistance in advanced hepatocellular carcinoma. , 1996, European journal of cancer.

[4]  H. Rhim,et al.  Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies , 2009, Hepatology.

[5]  R. Howard,et al.  Liver transplantation for hepatocellular carcinoma. , 2001, Minerva chirurgica.

[6]  H. Hasegawa,et al.  A Prospective Randomized Trial of the Preventive Effect of Pre‐operative Transcatheter Arterial Embolization against Recurrence of Hepatocellular Carcinoma , 1996, Japanese journal of cancer research : Gann.

[7]  J. Joh,et al.  Liver transplantation for adult patients with hepatocellular carcinoma in Korea: Comparison between cadaveric donor and living donor liver transplantations , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[8]  W. Jarnagin,et al.  Predictors and patterns of recurrence after resection of hepatocellular carcinoma. , 2003, Journal of the American College of Surgeons.

[9]  S. Fan,et al.  Extended Hepatic Resection for Hepatocellular Carcinoma in Patients with Cirrhosis: Is It Justified? , 2002, Annals of surgery.

[10]  A. Bartolucci,et al.  Phase II evaluation of doxorubicin plus bleomycin in hepatocellular carcinoma: a Southeastern Cancer Study Group trial. , 1984, Cancer treatment reports.

[11]  S. Ahn,et al.  Repetitive short‐course hepatic arterial infusion chemotherapy with high‐dose 5‐fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma , 2007, Cancer.

[12]  J. Whang‐Peng,et al.  Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. , 1998, British Journal of Cancer.

[13]  C. Horng,et al.  Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. , 2000, International journal of radiation oncology, biology, physics.

[14]  W. Lau,et al.  Partial Hepatectomy With Wide Versus Narrow Resection Margin for Solitary Hepatocellular Carcinoma: A Prospective Randomized Trial , 2007, Annals of surgery.

[15]  Ding‐Shinn Chen,et al.  Chronic oral etoposide and tamoxifen in the treatment of far‐advanced hepatocellular carcinoma , 1996, Cancer.

[16]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[17]  S. Fan,et al.  Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. , 1998, Archives of surgery.

[18]  T. Muto,et al.  Predictors of successful hepatic resection: Prognostic usefulness of hepatic asialoglycoprotein receptor analysis , 2002, World Journal of Surgery.

[19]  O. Matsui,et al.  Postoperative adjuvant hepatic arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma , 1994, Hepatology.

[20]  S. Feng,et al.  Allocation policy for hepatocellular carcinoma in the MELD era: Room for improvement? , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[21]  P. Rougier,et al.  Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  F. Izzo,et al.  Identification and Screening of 416 Patients with Chronic Hepatitis at High Risk to Develop Hepatocellular Cancer , 1995, Annals of surgery.

[23]  Maria Hawkins,et al.  Reproducibility of liver position using active breathing coordinator for liver cancer radiotherapy. , 2006, International journal of radiation oncology, biology, physics.

[24]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[25]  Jeffrey W. Clark,et al.  A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma , 2002, Cancer.

[26]  M. Colombo,et al.  The natural history of hepatocellular carcinoma. , 2002, Toxicology.

[27]  A. Burroughs,et al.  Is transarterial chemoembolization an option for all patients with unresectable hepatocellular carcinoma? , 2004, Nature Clinical Practice Gastroenterology &Hepatology.

[28]  Samir Gupta,et al.  Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. , 2003, Annals of internal medicine.

[29]  M. Gonen,et al.  Operative Blood Loss Independently Predicts Recurrence and Survival After Resection of Hepatocellular Carcinoma , 2009, Annals of surgery.

[30]  J. Llovet,et al.  Hepatocellular carcinoma: present status and future prospects. , 2003, Journal of hepatology.

[31]  W. Henderson,et al.  Predictive Indices of Morbidity and Mortality After Liver Resection , 2006, Annals of surgery.

[32]  S. Wadler,et al.  Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Bruix,et al.  Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation , 1999, Hepatology.

[34]  T. Kawabe,et al.  A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. , 2005, Gastroenterology.

[35]  S. Zangos,et al.  Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update , 2007, European Radiology.

[36]  S. Dymarkowski,et al.  Expression of multidrug resistance‐associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[37]  P. Liang,et al.  Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. , 2005, Radiology.

[38]  B. Kim,et al.  Salvage liver transplantation for recurrent hepatocellular carcinoma after liver resection: feasibility of the Milan criteria and operative risk. , 2008, Transplantation proceedings.

[39]  Chien-Fang Yang,et al.  Transcatheter arterial chemoembolization for hepatocellular carcinoma , 2004, Cancer Chemotherapy and Pharmacology.

[40]  Eleni Liapi,et al.  Transcatheter and ablative therapeutic approaches for solid malignancies. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  L. Ellis,et al.  Simplified staging for hepatocellular carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  H. El‐Serag.  Hepatocellular carcinoma: an epidemiologic view. , 2002, Journal of clinical gastroenterology.

[43]  K. Soo,et al.  Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. , 2009, The Cochrane database of systematic reviews.

[44]  Henry A. Pitt,et al.  Ablation of liver metastasis: Is preoperative imaging sufficiently accurate? , 2001, Journal of Gastrointestinal Surgery.

[45]  Zongli Zhang,et al.  Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. , 2008, JAMA.

[46]  K. Man,et al.  Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy , 1997, The British journal of surgery.

[47]  A. Sugioka,et al.  Hepatic resection for hepatocellular carcinoma. , 1990, Surgery.

[48]  M. Kojiro,et al.  Pathology of hepatocellular carcinoma in Japan: 232 consecutive cases autopsied in ten years , 1983, Cancer.

[49]  M. Makuuchi,et al.  The surgical approach to HCC: Our progress and results in Japan , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[50]  J. Belghiti.  Resection and liver transplantation for HCC , 2009, Journal of Gastroenterology.

[51]  H. Ishii,et al.  Technical considerations for fractionated stereotactic radiotherapy of hepatocellular carcinoma. , 1997, Japanese journal of clinical oncology.

[52]  G. Chau,et al.  Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma. , 2006, Journal of the American College of Surgeons.

[53]  N. Nagasue,et al.  Assessment of pattern and treatment of intrahepatic recurrence after resection of hepatocellular carcinoma. , 1990, Surgery, gynecology & obstetrics.

[54]  Ding‐Shinn Chen,et al.  Percutaneous Ethanol Injection Versus Surgical Resection for the Treatment of Small Hepatocellular Carcinoma: A Prospective Study , 2005, Annals of surgery.

[55]  W. Jarnagin,et al.  Resection of Hepatocellular Carcinoma in Patients Otherwise Eligible for Transplantation , 2003, Annals of surgery.

[56]  R. T. Ten Haken,et al.  Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  T. Livraghi,et al.  No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. , 1995, Journal of hepatology.

[58]  W. Lau,et al.  A Prospective, Randomized, Controlled Trial of Preoperative Transarterial Chemoembolization for Resectable Large Hepatocellular Carcinoma , 2009, Annals of surgery.

[59]  D. Samuel,et al.  Liver Resection as a Bridge to Transplantation for Hepatocellular Carcinoma on Cirrhosis: A Reasonable Strategy? , 2003, Annals of surgery.

[60]  M. Cardillo,et al.  Surgical treatment of hepatocellular cancer in the era of hepatic transplantation. , 2003, Journal of the American College of Surgeons.

[61]  Y. Guan,et al.  Interventional treatments for hepatocellular carcinoma. , 2006, Hepatobiliary & pancreatic diseases international : HBPD INT.

[62]  Samir Gupta,et al.  Test Characteristics of -Fetoprotein for Detecting Hepatocellular Carcinoma in Patients with Hepatitis C , 2003, Annals of Internal Medicine.

[63]  A. Zhu.  Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? , 2006, The oncologist.

[64]  S. Cha,et al.  Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of end-stage liver disease (MELD) score predicts perioperative mortality , 2005, Journal of Gastrointestinal Surgery.

[65]  I. Ng,et al.  Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma , 2007, The British journal of surgery.

[66]  C. Svensson,et al.  Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma , 2007, Acta oncologica.

[67]  M. Satti,et al.  Primary hepatocellular carcinoma in the eastern province of Saudi Arabia: treatment with combination chemotherapy using 5-fluorouracil, Adriamycin and mitomycin-C. , 1985, Hepato-gastroenterology.

[68]  S. Fan,et al.  Long-Term Survival and Pattern of Recurrence After Resection of Small Hepatocellular Carcinoma in Patients With Preserved Liver Function: Implications for a Strategy of Salvage Transplantation , 2002, Annals of surgery.

[69]  Linlang Guo,et al.  Expression of Tyrosine Kinase Etk/Bmx and Its Relationship with AP-1- and NF-κB-Associated Proteins in Hepatocellular Carcinoma , 2008, Oncology.

[70]  Hung-Ming Wang,et al.  Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma , 2000, Cancer.

[71]  V. Mazzaferro,et al.  Resection and Liver Transplantation for Hepatocellular Carcinoma , 2005, Seminars in liver disease.

[72]  Zeng-chen Ma,et al.  Surgery of small hepatocellular carcinoma. Analysis of 144 cases , 1989, Cancer.

[73]  Junji Konishi,et al.  Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. , 2002, Radiology.

[74]  P. Gibbs,et al.  Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  A. Sardi,et al.  Intraoperative Ultrasound (IOUS) is Essential in the Management of Metastatic Colorectal Liver Lesions , 2000, The American surgeon.

[76]  Ping Liang,et al.  Microwave Ablation of Hepatocellular Carcinoma , 2007, Oncology.

[77]  S. Fan,et al.  The role and limitation of living donor liver transplantation for hepatocellular carcinoma , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[78]  J. Cebon,et al.  Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide , 2006, British Journal of Cancer.

[79]  L. Ellis,et al.  Comparison of Clinicopathologic Characteristics and Outcomes After Resection in Patients With Hepatocellular Carcinoma Treated in the United States, France, and Japan , 2003, Annals of surgery.

[80]  D. Lu,et al.  Liver Transplantation Criteria For Hepatocellular Carcinoma Should Be Expanded: A 22-Year Experience With 467 Patients at UCLA , 2007, Annals of surgery.

[81]  Xiao-dong Lin,et al.  Local injection therapy for hepatocellular carcinoma. , 2006, Hepatobiliary & pancreatic diseases international : HBPD INT.

[82]  S. Pignata,et al.  Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial , 1998, The Lancet.

[83]  C. Scudamore,et al.  Indocyanine green clearance as a predictor of successful hepatic resection in cirrhotic patients. , 1992, American journal of surgery.

[84]  S. Fan,et al.  Efficacy and Tolerability of Low-Dose Thalidomide as First-Line Systemic Treatment of Patients with Advanced Hepatocellular Carcinoma , 2007, Oncology.

[85]  P. Galle,et al.  Systemic Therapies in Hepatocellular Carcinoma , 2009, Digestive Diseases.

[86]  E. Abdalla,et al.  Portal vein embolization: rationale, technique and future prospects , 2001, The British journal of surgery.

[87]  S. Kitano,et al.  Short- and Long-Term Outcomes after Hepatic Resection for Hepatocellular Carcinoma with Concomitant Esophageal Varices in Patients with Cirrhosis , 2008, Annals of Surgical Oncology.

[88]  M. Sata,et al.  Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis , 2002, Cancer.

[89]  S. Gallinger,et al.  Prognosis and Results After Resection of Very Large (≥10 cm) Hepatocellular Carcinoma , 2007, Journal of Gastrointestinal Surgery.

[90]  H. Bismuth,et al.  Surgical treatment of hepatocellular carcinomas in noncirrhotic liver: Experience with 68 liver resections , 2004, World Journal of Surgery.

[91]  J. Belghiti,et al.  Portal Vein Occlusion Prior to Extensive Resection in Colorectal Liver Metastasis: A Necessity Rather than an Option! , 2009, Annals of Surgical Oncology.

[92]  G. Ercolani,et al.  Improved Results of Liver Resection for Hepatocellular Carcinoma on Cirrhosis Give the Procedure Added Value , 2001, Annals of surgery.

[93]  Angelo Andriulli,et al.  Radiofrequency Thermal Ablation vs. Percutaneous Ethanol Injection for Small Hepatocellular Carcinoma in Cirrhosis: Meta-Analysis of Randomized Controlled Trials , 2009, The American Journal of Gastroenterology.

[94]  M. Choi,et al.  Long-term Results of Percutaneous Ethanol Injection for the Treatment of Hepatocellular Carcinoma in Korea , 2006, Korean journal of radiology.

[95]  M. Makuuchi,et al.  Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. , 2008, Gastroenterology.

[96]  N. Heaton,et al.  Hepatocellular carcinoma: defining the place of surgery in an era of organ shortage. , 2008, World journal of gastroenterology.

[97]  J. Geschwind,et al.  The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  Eva Pagano,et al.  Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial , 2008, Scandinavian journal of gastroenterology.

[99]  K. Han,et al.  Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. , 1999, International journal of radiation oncology, biology, physics.

[100]  G. Belli,et al.  Laparoscopic versus open liver resection for hepatocellular carcinoma in patients with histologically proven cirrhosis: short- and middle-term results , 2007, Surgical Endoscopy.

[101]  P. Johnson,et al.  Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. , 1987, Cancer treatment reports.

[102]  P. Gibbs,et al.  A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy , 2005, BMC Cancer.

[103]  P. Lopez,et al.  Management of hepatocellular carcinoma. , 2007, Clinics in liver disease.

[104]  F. Izzo,et al.  Outcome of 67 patients with hepatocellular cancer detected during screening of 1125 patients with chronic hepatitis. , 1998, Annals of surgery.

[105]  S. Fan,et al.  Improving Perioperative Outcome Expands the Role of Hepatectomy in Management of Benign and Malignant Hepatobiliary Diseases: Analysis of 1222 Consecutive Patients From a Prospective Database , 2004, Annals of surgery.

[106]  D. Pateron,et al.  Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. , 1994, Journal of hepatology.

[107]  I. Penn.  Hepatic transplantation for primary and metastatic cancers of the liver. , 1991, Surgery.

[108]  R. Poon.  Differentiating Early and Late Recurrences After Resection of HCC in Cirrhotic Patients: Implications on Surveillance, Prevention, and Treatment Strategies , 2009, Annals of surgical oncology.

[109]  E. Henderson,et al.  Phase II trial of mitoxantrone in advanced primary liver cancer: a Cancer and Leukemia Group B Study. , 1986, Cancer treatment reports.

[110]  Jeffrey W. Clark,et al.  A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. , 2005, The oncologist.

[111]  Yi-Cheng Chen,et al.  Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. , 2004, Gastroenterology.

[112]  D. Wolf.  Screening for hepatocellular carcinoma: Is it cost‐effective? , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[113]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[114]  M. Makuuchi,et al.  Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. , 2006, Gastroenterology.

[115]  W. Lau,et al.  A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma , 2006, Annals of surgery.

[116]  W. Cacheux,et al.  Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis , 2005, Hepatology.

[117]  M. Moroni,et al.  Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study. , 1997, European journal of cancer.

[118]  S. Rafii,et al.  Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  M. Makuuchi,et al.  Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. , 1993, Japanese journal of clinical oncology.

[120]  M. Ho,et al.  Feasibility of salvage liver transplantation for patients with recurrent hepatocellular carcinoma , 2005, Clinical transplantation.

[121]  Jeffrey S. Morris,et al.  Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  S. zovato,et al.  A phase II study of pegylated liposomial doxorubicin (PLD) and gemcitabine (G) in the treatment of hepatocellular carcinoma (HCC) not suitable for loco-regional therapy , 2007 .

[123]  Charles M. Miller,et al.  Hepatocellular carcinoma: A prime indication for living donor liver transplantation , 2002, Journal of Gastrointestinal Surgery.

[124]  N. Kemeny,et al.  Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump , 1992, Cancer.

[125]  E. Abdalla,et al.  Resection Prior to Liver Transplantation for Hepatocellular Carcinoma , 2003, Annals of surgery.

[126]  A. Burroughs,et al.  Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma , 2008, Expert review of gastroenterology & hepatology.

[127]  M. Kudo,et al.  Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score) , 2003, Journal of Gastroenterology.

[128]  S. Thorgeirsson,et al.  Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. , 2006, Gastroenterology.

[129]  M. Schwartz.  Liver Transplantation: the Preferred Treatment for Early Hepatocellular Carcinoma in the Setting of Cirrhosis? , 2007, Annals of Surgical Oncology.

[130]  D. Amadori,et al.  Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[131]  M. Büchler,et al.  Preoperative Galactose Elimination Capacity Predicts Complications and Survival After Hepatic Resection , 2002, Annals of surgery.

[132]  Q. Ye,et al.  Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy , 2007, Journal of surgical oncology.

[133]  K. Tanikawa,et al.  Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. The liver cancer study group of japan , 1994, Cancer.

[134]  M. Choti,et al.  Predictors of Survival After Resection of Early Hepatocellular Carcinoma , 2009, Annals of surgery.

[135]  P. Gibbs,et al.  Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies , 2005, Internal medicine journal.

[136]  M. Rosen,et al.  Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study , 2007 .

[137]  J. Galmiche,et al.  Percutaneous ethanol injection vs. resection in patients with small single hepatocellular carcinoma: a retrospective case–control study with cost analysis , 2002, Alimentary pharmacology & therapeutics.

[138]  D. V. van Thiel,et al.  Hepatic resection versus transplantation for hepatocellular carcinoma. , 1991, Annals of surgery.

[139]  U. Haedinger,et al.  Stereotactic radiotherapy of primary liver cancer and hepatic metastases , 2006, Acta oncologica.

[140]  J. Pignon,et al.  Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring , 2007 .

[141]  N. Habib,et al.  Preoperative Portal Vein Embolization for Major Liver Resection: A Meta-Analysis , 2008, Annals of surgery.

[142]  C. Suh,et al.  Dose-response relationship in local radiotherapy for hepatocellular carcinoma. , 2001, International journal of radiation oncology, biology, physics.

[143]  M. Yoshino,et al.  A phase II study of etoposide in patients with hepatocellular carcinoma by the Tokyo Liver Cancer Chemotherapy Study Group. , 1989, Japanese journal of clinical oncology.

[144]  J. Bruix,et al.  Prognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patients , 1990, Hepatology.

[145]  M. Mulcahy,et al.  Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. , 2008, World journal of gastroenterology.

[146]  John Wong,et al.  Natural History of Untreated Nonsurgical Hepatocellular Carcinoma , 2005, The American Journal of Gastroenterology.

[147]  M. Ducreux,et al.  Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. , 2006, European journal of cancer.

[148]  Shou-Dong Lee,et al.  The Model for End-Stage Liver Disease Based Cancer Staging Systems Are Better Prognostic Models for Hepatocellular Carcinoma: A Prospective Sequential Survey , 2007, The American Journal of Gastroenterology.

[149]  R. Yamada,et al.  Hepatic artery embolization in 120 patients with unresectable hepatoma. , 1983, Radiology.

[150]  L. Papoz,et al.  Prognostic factors in patients with hepatocellular carcinoma attempts for the selection of patients with prolonged survival , 1987, Cancer.

[151]  M. Abecassis,et al.  Living donor liver transplantation for hepatocellular carcinoma. , 2004, Gastroenterology.

[152]  M. Gonen,et al.  Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma , 2005, Cancer.

[153]  F. Berr,et al.  A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[154]  C-J. S. Lin,et al.  Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less , 2005, Gut.

[155]  H. Seno,et al.  Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5‐fluorouracil, epirubicin and mitomycin C , 1999, Journal of gastroenterology and hepatology.

[156]  K. Soo,et al.  High‐dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial , 2002, Hepatology.

[157]  Carlo Bartolozzi,et al.  Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. , 2003, Radiology.

[158]  J. Doroshow,et al.  5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. , 1995, Cancer investigation.

[159]  W. Jarnagin,et al.  An analysis of 412 cases of hepatocellular carcinoma at a Western center. , 1999, Annals of surgery.

[160]  A. Lok,et al.  Hepatocellular Carcinoma Recurrence and Death Following Living and Deceased Donor Liver Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[161]  Toshihito Seki,et al.  Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma , 1994, Cancer.

[162]  N. Nagasue,et al.  The natural history of hepatocellular carcinoma. A study of 100 untreated cases , 1984, Cancer.

[163]  G. Stansby,et al.  Surgery of small hepatocellular carcinoma. , 1990, Cancer.

[164]  M. Torbenson,et al.  mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms , 2004, Clinical Cancer Research.

[165]  Jeffrey S. Morris,et al.  Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma , 2007, Cancer.

[166]  H. Jang,et al.  Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma. , 2006, Japanese journal of clinical oncology.

[167]  H. El‐Serag,et al.  Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.

[168]  K. Aoki,et al.  A phase 2 study of cisplatin in patients with hepatocellular carcinoma. , 1993, Oncology.

[169]  K. Sugimura,et al.  Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. , 2003, International journal of radiation oncology, biology, physics.

[170]  Kenneth G. Thurston,et al.  Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. , 2005, Journal of vascular and interventional radiology : JVIR.

[171]  A. Venook,et al.  Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival , 2001, Hepatology.

[172]  H. Hasegawa,et al.  Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients , 1985, Cancer.

[173]  M. Gnant,et al.  Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma , 2001, British Journal of Cancer.

[174]  Manal M. Hassan,et al.  Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma , 2004, Cancer.

[175]  R. T. Ten Haken,et al.  Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[176]  W. Helton,et al.  Radiofrequency ablation of primary and metastatic liver tumors: a critical review of the literature. , 2008, American journal of surgery.

[177]  W. Lau,et al.  Adjuvant Intra-arterial Iodine-131-labeled Lipiodol for Resectable Hepatocellular Carcinoma: A Prospective Randomized Trial—Update on 5-Year and 10-Year Survival , 2008, Annals of surgery.

[178]  M. Vivarelli,et al.  Impact of model for end‐stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[179]  M. Makuuchi,et al.  Selection Criteria for Repeat Hepatectomy in Patients With Recurrent Hepatocellular Carcinoma , 2003, Annals of surgery.

[180]  S. Fan,et al.  Prognosis After Hepatic Resection for Stage IVA Hepatocellular Carcinoma: A Need for Reclassification , 2003, Annals of surgery.

[181]  C. Suh,et al.  Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

[182]  M. Abecassis,et al.  AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. , 2003, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[183]  S. Altekruse,et al.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[184]  Y. N. Park,et al.  Outcome after curative resection for a huge (>or=10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. , 2009, American journal of surgery.

[185]  C. Ker,et al.  Laparoscopic Liver Surgery for Patients with Hepatocellular Carcinoma , 2008, Annals of Surgical Oncology.

[186]  V. Mazzaferro,et al.  The effect of estrogen and tamoxifen on hepatocyte proliferation in Vivo and in Vitro , 1989, Hepatology.

[187]  H. Yoo,et al.  Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[188]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[189]  C. Porta,et al.  Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[190]  S. Park,et al.  Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma , 2006, BMC Cancer.

[191]  F. Lee,et al.  Expanded treatment of hepatic tumors with radiofrequency ablation and cryoablation. , 2005, Oncology.

[192]  T. Pawlik,et al.  Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. , 2005, Archives of surgery.

[193]  A. Gardini,et al.  Liver Resection for Hepatocellular Carcinoma on Cirrhosis: Univariate and Multivariate Analysis of Risk Factors for Intrahepatic Recurrence , 2003, Annals of surgery.

[194]  Kenzo Kobayashi,et al.  Prospective study of α‐fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma , 1994 .

[195]  Joon-Oh Park,et al.  Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma , 2004, Cancer Chemotherapy and Pharmacology.

[196]  K. Shirabe,et al.  [Prognostic factors in patients with hepatocellular carcinoma]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.

[197]  Derek Y. Chiang,et al.  Genomics and signaling pathways in hepatocellular carcinoma. , 2007, Seminars in liver disease.

[198]  M. Makuuchi,et al.  Results of surgical and nonsurgical treatment for small‐sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan , 2000, Hepatology.

[199]  John Wong,et al.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.

[200]  W. Lau,et al.  The Current Role of Radiofrequency Ablation in the Management of Hepatocellular Carcinoma: A Systematic Review , 2009, Annals of surgery.

[201]  F. Izzo,et al.  Hepatic Resection and Percutaneous Ethanol Injection as Treatments of Small Hepatocellular Carcinoma: A Cancer of the Liver Italian Program (CLIP 08) Retrospective Case–Control Study , 2003, Journal of clinical gastroenterology.

[202]  W. Lau,et al.  A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. , 2005, Journal of the National Cancer Institute.

[203]  S. Fan,et al.  Transcatheter arterial chemoembolization in inoperable hepatocellular carcinoma: four-year follow-up. , 1996, Journal of vascular and interventional radiology : JVIR.

[204]  V. Mazzaferro,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[205]  D. Ihde,et al.  Clinical trials in primary hepatocellular carcinoma: current status and future directions. , 1988, Cancer treatment reviews.

[206]  Steven A. Curley,et al.  Radiofrequency Ablation of Hepatocellular Cancer in 110 Patients With Cirrhosis , 2000, Annals of surgery.

[207]  H. Fukuda,et al.  Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. , 2005, Journal of hepatology.

[208]  F. Lohr,et al.  Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[209]  M. Kessler,et al.  Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers. , 1997, International journal of radiation oncology, biology, physics.

[210]  Ching-lung Lai,et al.  Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial , 1988, Cancer.

[211]  P. Tiollais,et al.  Hepatitis B virus. , 1991, Scientific American.

[212]  Jeffrey W. Clark,et al.  Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma , 2007, Cancer.

[213]  G. Abou-Alfa.  Hepatocellular carcinoma: molecular biology and therapy. , 2006, Seminars in oncology.

[214]  Maria Hawkins,et al.  Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[215]  H. Hsu,et al.  Surgical resection for recurrent hepatocellular carcinoma: prognosis and analysis of risk factors. , 1996, Surgery.

[216]  S. Tsao,et al.  Phase II trial of epirubicin in hepatoma. , 1986, Cancer treatment reports.

[217]  S. Hahn,et al.  Hepatic resection compared to percutaneous ethanol injection for small hepatocellular carcinoma using propensity score matching , 2007, Journal of gastroenterology and hepatology.

[218]  K. Shirabe,et al.  Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. , 1996, Gastroenterology.

[219]  H. Blum,et al.  Serum markers of hepatocellular carcinoma. , 2006, Seminars in liver disease.

[220]  F. Giuliante,et al.  Liver resections for hepatocellular carcinoma in chronic liver disease: experience in an Italian centre. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[221]  K. Shirabe,et al.  Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma , 1996, Cancer.

[222]  V. Vilgrain,et al.  Portal Vein Embolization Before Right Hepatectomy: Prospective Clinical Trial , 2003, Annals of surgery.

[223]  T. Kiuchi,et al.  Living-donor liver transplantation for hepatocellular carcinoma , 2003, Transplantation.

[224]  T. Pawlik,et al.  Surgical Management of Early-Stage Hepatocellular Carcinoma: Resection or Transplantation? , 2008, Journal of Gastrointestinal Surgery.

[225]  J. Bruix,et al.  Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. , 1995, Gastroenterology.

[226]  W. Lau,et al.  Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[227]  Derek Y. Chiang,et al.  Pivotal role of mTOR signaling in hepatocellular carcinoma. , 2008, Gastroenterology.

[228]  M. Choi,et al.  Local radiotherapy for patients with unresectable hepatocellular carcinoma. , 2005, International journal of radiation oncology, biology, physics.

[229]  R. Beasley.  Hepatitis B virus. The major etiology of hepatocellular carcinoma , 1988, Cancer.

[230]  J. Seong,et al.  Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis , 2008, Cancer.

[231]  F. P'eng,et al.  Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: A reappraisal , 1995, The British journal of surgery.

[232]  T. Fleming,et al.  Phase II study of fludarabine phosphate in previously untreated patients with hepatoma: a Southwest Oncology Group Study. , 1987, Cancer treatment reports.

[233]  S. Shiina.  Japanese experience in ablation therapies for hepatocellular carcinoma , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[234]  F. Izzo,et al.  A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients , 1998, Hepatology.

[235]  W. Grigioni,et al.  The Role of Lymphadenectomy for Liver Tumors: Further Considerations on the Appropriateness of Treatment Strategy , 2004, Annals of surgery.

[236]  Ramon Planas,et al.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.

[237]  V. Herlea,et al.  Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma. , 2008, Journal of gastrointestinal and liver diseases : JGLD.

[238]  J. Bruix,et al.  Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation , 2002, Gut.

[239]  Alona Muzikansky,et al.  Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[240]  C. G. Child,et al.  Surgery and portal hypertension. , 1964, Major problems in clinical surgery.

[241]  M. Anscher,et al.  Hepatic toxicity resulting from cancer treatment. , 1995, International journal of radiation oncology, biology, physics.

[242]  H. Bismuth,et al.  Liver Resection Versus Transplantation for Hepatocellular Carcinoma in Cirrhotic Patients , 1993, Annals of surgery.

[243]  J. Abbruzzese,et al.  Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma (HCC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[244]  M. Makuuchi,et al.  Recurrence of hepatocellular carcinoma after surgery , 1996, The British journal of surgery.

[245]  K. Sugimachi,et al.  The indocyanine green test enables prediction of postoperative complications after hepatic resection , 1987, World Journal of Surgery.